RecruitMe Clinical Trial

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMERS DISEASE
Study of Gantenerumab in Subjects with Early Alzheimer's Disease (Prodromal to Mild)
Sponsor:F. Hoffmann-La Roche Ltd
Enrolling:Male and Female Patients
Age Range:Between 50 and 90 years old
IRB Number:AAAR9258
U.S. Government ID:NCT03444870
Contact: Evelyn Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information:

This is a randomized, double-blind, placebo-controlled, parallel-group study that will evaluate the efficacy and safety of gantenerumab versus placebo in participants with prodromal (very early form) to mild AD. Participants will have a chance of receiving either injections of gantenerumab or placebo as per the visit schedule. The primary efficacy assessment will be performed after about 2 years. It is anticipated that participants will then have the option of enrolling in an open-label extension study, in which they will get gantenerumab.

Do You Qualify?
Are you between the ages of 50-90 (inclusive)?YesNo
Have you been diagnosed with prodromal (very early form) to mild Alzheimer's disease?YesNo
Submit
Cancel
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Evelyn Dominguez
Email: edd5@cumc.columbia.edu
Phone: 212-305-2371